Avalon Investment & Advisory Dexcom Inc Transaction History

Avalon Investment & Advisory

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 08, 2021	SELL	$106.71 - $143.18 $58,370 - $78,319	-547 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$80.99 - $107.93 $21,462 - $28,601	-265 Reduced 32.64%	547 $234,000
Q1 2021 May 13, 2021	SELL	$84.79 - $104.74 $2.8 Million - $3.46 Million	-33,076 Reduced 97.6%	812 $292,000
Q4 2020 Feb 08, 2021	BUY	$78.0 - $104.5 $25,038 - $33,544	321 Added 0.96%	33,888 $12.5 Million
Q3 2020 Nov 04, 2020	SELL	$95.51 - $112.95 $138,393 - $163,664	-1,449 Reduced 4.14%	33,567 $13.8 Million
Q2 2020 Aug 07, 2020	SELL	$62.68 - $105.34 $261,689 - $439,794	-4,175 Reduced 10.65%	35,016 $14.2 Million
Q1 2020 May 05, 2020	BUY	$47.79 - $75.63 $1.87 Million - $2.96 Million	39,191 New	39,191 $10.6 Million

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Avalon Investment & Advisory, based on Form 13F filings with the SEC.

Stay updated on Avalon Investment & Advisory with notifications on news.